BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33906633)

  • 1. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.
    Venugopal A; Gillick-Walker J; Michalczyk A; Khasraw M; Ackland ML
    BMC Gastroenterol; 2021 Apr; 21(1):194. PubMed ID: 33906633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.
    Venugopal A; Michalczyk A; Khasraw M; Ackland ML
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
    Saller JJ; Haider M; Al-Diffalha S; Coppola D
    Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
    Modlin IM; Drozdov I; Kidd M
    PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
    Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
    Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
    Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
    Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression.
    Lassmann S; Bauer M; Rosenberg R; Nekarda H; Soong R; Rüger R; Höfler H; Werner M
    Int J Colorectal Dis; 2004 Mar; 19(2):87-94. PubMed ID: 13680284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.
    Rosenbaum JN; Guo Z; Baus RM; Werner H; Rehrauer WM; Lloyd RV
    Am J Clin Pathol; 2015 Oct; 144(4):579-91. PubMed ID: 26386079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas.
    Bari MF; Brown H; Nicholson AG; Kerr KM; Gosney JR; Wallace WA; Soomro I; Muller S; Peat D; Moore JD; Ward LA; Freidin MB; Lim E; Vatish M; Snead DR
    Histopathology; 2014 Mar; 64(4):547-56. PubMed ID: 24266897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
    González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
    Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
    Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
    Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
    Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
    Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
    Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours.
    Hussain F; Wang J; Ahmed R; Guest SK; Lam EW; Stamp G; El-Bahrawy M
    Cytokine; 2010 Feb; 49(2):134-40. PubMed ID: 20005738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
    Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
    Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.